Ultrasensitive Human Immunodeficiency Virus Type 1 Viral Load as a Marker of Treatment Choice for Simplification Strategies

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Sidonie Lambert-NiclotL Morand-Joubert

Abstract

Using 3 randomized Protease inhibitor (PI) monotherapy studies: Kalesolo, Dream and Monoi, we performed a pooled-analysis. Our objective was to determine in PI monotherapy and standard tritherapy: 1) distribution of ultrasensitive viral load (USVL) at week 96 (W96); 2) factors associated with virological failure (VF) at W96 and 3) factors associated with USVL<1 copy at W96. VF was defined as 2 consecutive measurements of Human Immunodeficiency Virus Type 1 RNA viral load>50 copies/mL and analysed in Intention-To-Treat. A logistic model was used to investigate which variables were predictive of a VF and Fisher test to investigate differences in USVL at W96. Among 609 patients, 73% were male with median age of 44.4 years (IQR 39.8-52.1), baseline CD4/CD8 ratio was 0.8 (IQR 0.6-1.10), baseline CD4 was 564.5/mm3 (IQR 422-707) and 59% presented a baseline USVL<1 copy/mL. At W96, the proportion of USVL<1 copy/mL was significantly different between PI monotherapy and standard tritherapy in pooled-analysis (65% versus 74%; p=0.04). Overall, baseline USVL<1copy/mL, tritherapy and to be a female were associated with USVL<1 copy/mL at W96 (p<0.0001, p=0.049 and p=0.006). In PI monotherapy receiving DRV/r was associated with USVL<1 copy/mL...Continue Reading

References

Mar 12, 2008·Proceedings of the National Academy of Sciences of the United States of America·Sarah PalmerMartin S King
Jul 8, 2008·The Journal of Allergy and Clinical Immunology·Lin Shen, Robert F Siliciano
Dec 31, 2008·AIDS·Wouter F W BiermanCharles A B Boucher
Sep 17, 2010·The Journal of Antimicrobial Chemotherapy·Jean-Luc MeynardUNKNOWN KALESOLO Study Group
Dec 16, 2010·AIDS·Stéphanie Haïm-BoukobzaAnne-Geneviève Marcelin
Sep 16, 2011·The Journal of Infectious Diseases·Sidonie Lambert-NiclotAnne-Genevieve Marcelin
Oct 12, 2011·The Journal of Antimicrobial Chemotherapy·Nicola GianottiAntonella Castagna
Dec 14, 2011·The Journal of Antimicrobial Chemotherapy·M A ValantinUNKNOWN MONOI ANRS 136 Study Group
Jan 13, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Tomas DoyleAnna Maria Geretti
Apr 7, 2012·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Franco MaggioloSebastiano Leone
Jun 15, 2012·AIDS·Marguerite GuiguetUNKNOWN FHDH-ANRS CO4
Sep 10, 2013·International Journal of STD & AIDS·Jose ArribasChristiane Moecklinghoff
Jan 18, 2014·Antiviral Therapy·Alicia Gutierrez-ValenciaLuis F López-Cortés
Jun 21, 2014·The Journal of Antimicrobial Chemotherapy·Charlotte CharpentierRoland Landman
Sep 10, 2014·Clinical Pharmacokinetics·Andrea CalcagnoStefano Bonora
May 30, 2015·The Journal of Antimicrobial Chemotherapy·Tu-Anh TranYassine Taoufik
Oct 2, 2015·The Lancet. HIV·Nicholas I PatonUNKNOWN Protease Inhibitor Monotherapy Versus Ongoing Triple Therapy (PIVOT) Trial Team
Jul 13, 2016·JAMA : the Journal of the American Medical Association·Huldrych F GünthardPaul A Volberding
Oct 27, 2016·AIDS·Wolfgang StöhrUNKNOWN Protease Inhibitor Monotherapy Versus Ongoing Triple Therapy (PIVOT) Trial Team

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.